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Abstract 
Background Despite promising results following transcatheter aortic valve implantation (TAVI), 
several relevant challenges still remain. To overcome these issues, new generation devices have 
been developed. The purpose of the present study was to determine whether TAVI with the new 
self-expanding repositionable Evolut R offers potential benefits compared to the preceding 
CoreValve, using propensity matching. 
Methods Between June 2007 and November 2015, 2148 consecutive patients undergoing TAVI 
either CoreValve (n=1846) or Evolut R (n=302) were prospectively included in the Italian TAVI 
ClinicalService
®
 project. For the purpose of our analysis 211 patients treated with the Evolut R 
were matched to 211 patients treated with the CoreValve. An independent core laboratory reviewed 
all angiographic procedural data and an independent clinical events committee adjudicated all 
events.  
Results Patients treated with Evolut R experienced higher 1-year overall survival (log rank test 
p=0.046) and a significantly lower incidence of major vascular access complications, bleeding 
events and acute kidney injury compared to patients treated with the CoreValve. Recapture 
manoeuvres to optimize valve deployment were performed 44 times, allowing a less implantation 
depth for the Evolut R. As a consequence, the rate of more than mild paravalvular leak and new 
permanent pacemaker was lower in patients receiving the Evolut R. 
Conclusion In this matched comparison of high surgical risk patients undergoing TAVI, the use of 
Evolut R was associated with a significant survival benefit at 1 year compared with the CoreValve. 
This was driven by lower incidence of periprocedural complications and higher rates of correct 
anatomic positioning.  
Keywords: self-expandable transcatheter aortic valve, transcatheter aortic valve implantation 
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Introduction 
Transcatheter aortic valve implantation (TAVI) is now the treatment option of choice for 
symptomatic severe aortic stenosis in patients judged inoperable or at high surgical risk, 
demonstrating excellent procedural results with sustained clinical outcomes (1) (2). Although TAVI 
has been proven to be non-inferior or even superior to surgical aortic valve replacement in terms of 
all-cause mortality, challenges such as paravalvular leak, requirement for permanent pacemaker 
implantation, vascular access complications and stroke still exist and add significant morbidity to 
TAVI recipients (3) (4) (5) (6) (7) (8). First-generation devices with the use of larger diameter 
catheters (18-F to 24-F) may explain the higher incidence of procedure-related complications in the 
early phase of TAVI (9) (10). In the last few years the increasing operator experience with the 
development of second generations device and smaller profile delivery system have resulted in a 
significant improvement of procedural outcomes (11) (12) (13) (14) (15) (16).  
Recently, the latest generation of the CoreValve, the resheathable Evolut R, with enhanced features 
that allow the valve to be recaptured and repositioned during deployment, might further enhance 
TAVI performance (17) (18) (19). Despite initial promising results from the CE mark trial 
evaluating the safety and clinical performance of the Evolut R, it is not well established whether the 
new capabilities of Evolut R will translate into improved procedural and clinical outcomes 
compared with its predecessor in extensive clinical use (18). Therefore the aim of the present study 
was to analyse and compare all patients who underwent TAVI with the Corevalve or Evolut R in 
the prospective national Italian TAVI registry using propensity matching. 
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Methods 
Patient population. Starting from June 2007, all consecutive patients with severe aortic stenosis 
undergoing TAVI with either the CoreValve or the resheathable CoreValve Evolut R were 
prospectively included in the Italian ClinicalService® Project. This is an on-going nation-based 
clinical data repository and medical care project aimed at describing and improving the use of 
implantable devices in Italian clinical practice already described elsewhere (20) (21). From June 
2007 to November 2015 patients were treated with the CoreValve, whereas the Evolut R was used 
from November 2014 until November 2015. For the purpose of the analysis, first 3 CoreValve 
implants and first 3 Evolut implants per center were excluded. Patients receiving the CoreValve 31 
mm were also excluded from the analysis due to lack of a larger than 29 mm Evolut R device.  
Clinical follow-up was performed either by phone or in the outpatient clinic. Each patient signed an 
informed consent form for participation in the ClinicalService
®
 project. 
Implantation Procedure. TAVI procedures were mainly performed under local anesthesia with 
mild systemic sedative/analgesic treatment, according to patient collaboration (22). The trans-
femoral route was the default access site, with percutaneous puncture sites closed with suture-based 
closure device (one Prostar XL or two ProGlide systems, Abbott Vascular Inc.). Other access sites 
including trans-aortic and trans-subclavian were considered if the trans-femoral route was 
contraindicated.  
Valve devices. The Medtronic CoreValve (Medtronic Inc, Minneapolis, Minnesota) is a self-
expandable valve that consists of a trileaflet porcine pericardial valve mounted on a nitinol frame 
and requires the insertion of an 18 Fr sheath for delivery (4).  
The latest CoreValve generation, the EvolutR with inLine Sheath EnVeo R delivery catheter, is a 
novel transcatheter heart valve system with enhanced features that allow to resheath or recapture the 
partially deployed prosthesis (up to 80% of maximal deployment) in order to reposition or retrieve 
the implant (18). The reduced outflow height helps prevents valve interference from the ascending 
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aorta that may influence valve position within angulated anatomies, while the extended skirt and a 
more cylindrical shape of the lower part frame create a longer landing zone for better sealing 
reducing significant paravalvular leak. Furthermore, the built-in inline sheath allows for the whole 
system to be inserted into a patient without the need for a separated access sheath, reducing the 
overall profile of the system, equivalent to the outer diameter of a 14-Fr. As a consequence, the 
minimal access vessel diameter suitable for Evolut R implantation is 5 mm compared to 6 mm for 
the CoreValve.  
Definitions. Primary outcome of interest was freedom from 12 months all-cause mortality after 
TAVI. Secondary endpoints were periprocedural adverse events including paravalvular leak, 
bleeding, vascular access sites complications, stroke, acute kidney injury and new permanent 
pacemaker implantation.  
Events were defined according to the Valve Academic Research Consortium-2 (VARC-2) (23). 
Measurements of implantation depth were performed on angiographic images as previously 
described (24). “Correct implantation” was defined as a depth ≤6 mm below the annulus plane, and 
a depth >6 mm was considered to be a low implantation. Angiographic assessment of post-
procedural aortic regurgitation severity was performed according to Sellers classification (25). The 
grade of paravalvular leak at discharge was assessed by transthoracic echocardiography according 
to VARC-2 guidelines (23). An independent core laboratory reviewed all angiographic procedural 
data (implantation depth, final angiographic aortic regurgitation, number of full and partial 
recaptures), and an independent clinical events committee adjudicated all events.  
Statistical analysis. Continuous data were summarized as mean and standard deviation or median 
and 25
th
-75
th
 percentiles in case of skewed distributions. Absolute and relative frequencies were 
reported for categorical variables. Continuous variables were compared using the Wilcoxon test. 
Normality of distribution was tested, calculating skewness and kurtosis values. Comparisons of 
categorical variables were performed using Chi-square test. A 2-tailed value of p<0.05 was 
considered significant. Overall survival was studied by means of a Cox model and Kaplan–Meier 
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curves were reported. Proportionality of hazards was tested using the Shoenfeld residuals.  
Propensity score matching was performed to adjust for differences in baseline characteristics 
between the CoreValve and the Evolut groups. The propensity score was calculated by using a 
logistic regression model that included the following variables: sex, hypertension, diabetes mellitus, 
renal disease, coronary artery disease, peripheral artery disease, chronic obstructive pulmonary 
disease, atrial fibrillation, left bundle branch block, mean transaortic pressure gradient and  NYHA 
III-IV.  Matching was performed by randomly selecting a patient treated with Evolut R and looking 
for the patient treated with the CoreValve with the nearest logit-transformed propensity score. The 
C-statistic was 0.67 showing good discrimination of the propensity-matching model. 
For statistical analysis, SAS 9 for Windows (SAS Inst. Inc., Cary, NC) was used. 
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Results 
Patient population. Of 2148 patients undergoing TAVI with a self-expanding valve, between June 
2007 to November 2015, 1846 were treated with the CoreValve and 302 patients were treated with 
the Evolut R. After propensity analysis, a total of 211 patients (Evolut R group) receiving Evolut R 
(31.8% male, 82±7 years, STS score 7.5±6.9) were matched to 211 patients (CoreValve group) 
receiving CoreValve (28.9% male, 83±6 years, STS score 7.3±5.4). All baseline characteristics of 
propensity-matched groups were well balanced (Table 1). 
Procedural data. Detailed procedural data are summarized in table 2. The majority of Evolut R and 
CoreValve patients were treated via the transfemoral route (86.2% vs. 82.5%; p=0.41) and under 
local anaesthesia (77.3% vs. 75.9%; p=0.75) without significant differences between the two 
groups. Device success according to VARC2 definitions tented to be lower in the Evolut R group 
(99.1% vs. 96.7%; p=0.09). Overall procedural time was similar in both groups whereas patients 
treated with the Evolut R received less contrast dye (156.4±69.0 ml vs. 184.6±81.9 ml; p=0.002). 
Evolut R patients were more likely to receive smaller sized valves (p=0.001) and were less 
frequently treated with balloon pre-dilatation (49.3% vs.. 71.6%, p<0.001) with a higher need for 
balloon post-dilatation after implantation (36.4% vs.. 18.9%, p<0.001), compared to the CoreValve 
patients.  
Evolut R valve repositioning was successfully performed 44 times by either resheating or 
recapturing, mostly due to initial deep positioning of the valve. There were 12 completed recaptures 
without valve related dysfunction requiring a repeat procedure. As consequence, the option to 
optimize valve position allowed a less ventricular implantation depth at the non-coronary cusp in 
the Evolut R group (Figure 1 A). In particular, in only on third of Evolut R patients the implantation 
depth was > 6 mm, while this was observed in more than half of CoreValve patients (26.2% vs. 
50.4%; p<0.001). Although not statistically significant, final angiography showed a clear trend 
toward lower grade of aortic regurgitation in Evolut R group (p=0.139; Figure 1 B).  
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In-hospital outcomes. Detailed in hospital clinical outcomes are presented in table 3. In hospital 
death was lower in the Evolut R group compared to CoreValve group (0.5% vs. 2.8%; p=0.054). 
Significant lower rate of life-threating bleeding (0.4% vs. 5.7%; p<0.001), major bleeding (1.4% vs. 
9.9%; p<0.001), major vascular access site complications (2.0% vs. 16.1%; p<0.001), need for 
transfusion >2 units of blood (1.4% vs. 8.1%; p=0.001) and acute kidney injury (9.4% vs. 22.2%; 
p<0.001) were observed for the Evolut R patients. No differences in myocardial infarction, any 
cerebrovascular events and device failure requiring reintervention were noted among the two 
groups. On the contrary, the incidence of major or disabling stroke tented to be higher in the Evolut 
R group, although not statistically different (1.4% vs.. 0.0%; p=0.089). New permanent pacemaker 
implantation rate and the length of hospital stay were significantly lower for patients treated with 
Evolut R (22.7% vs. 35.3%; p=0.008 and 7.5 days vs. 8.8 days; p=0.002, respectively). 
One hundred and fifty (71.1%) patients in the Evolut R group and 174 (82.2%) patients in the 
CoreValve group underwent predischarge transthoracic echocardiography (table 3). Peak and mean 
aortic transvalvular gradients decreased significantly in both groups (both p<0.001), with no cases 
of residual stenosis. There was a significant difference in predischarge paravalvular leak severity, 
with lower rate of moderate to severe paravalvular leak in Evolut R group compared with 
CoreValve group (9.0% vs. 16.7%; p=0.048) (Figure 1 C). 
Long-term outcomes.  One year follow-up data were available in 96.9% of patients, with survival 
status reported as of November 15, 2016. Median follow-up in the Evolut R and CoreValve groups 
was 365 (range 1 to 551) days and 365 (range 1 to 2671) days, respectively. The Kaplan-Meier 
survival curve for the 2 groups is shown in Figure 2. Patients treated with the Evolut R had a better 
long-term prognosis than patients treated with the CoreValve (HR 1.80, 95% CI 1.01 to 3.23, 
p=0.046). Survival curves began to diverge early, with significantly lower 30-day mortality in the 
Evolut R group compared to CoreValve group (1.0% vs. 7.2%; p=0.001). Actuarial survival rate at 
1 year was 91.9% in the Evolut R compared with 85.8% in the CoreValve group. 
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Discussion 
This study was sought to describe the differences in procedural and clinical outcomes of patients 
undergoing TAVI with the new self-expanding repositionable Evolut R versus the preceding 
CoreValve in the real clinical practice using propensity matching. 
The main findings of our report are: 1) Evolut R prosthesis was associated with a significant 
survival benefit with regard to 30 days and 1 year all cause mortality compared to CoreValve 
prosthesis; 2) this benefit was mainly driven by a reduction in vascular complications, bleeding and 
acute kidney injury; 3) the need for new pacemaker implantation was significantly lower for 
patients receiving the Evolut R; 4) the rate of moderate to severe paravalvular leak at discharge was 
decreased in Evolut R compared to CoreValve patients. 
Although the outcomes following TAVI have improved over the past years, challenges such as 
vascular access complications, bleeding, paravalvular leak, requirement for permanent pacemaker 
implantation and stroke still remain (5) (26). First generation devices have been extensively 
enhanced with refinement of delivery system in order to improve procedural and clinical outcomes. 
So far, studies comparing the use of newer second generation devices with first generation devices 
are currently of small sample size, mostly focused on balloon-expandable prosthesis and on short-
term follow-up (12) (13) (14) (15) (16). Recent studies, including a modest number of patients, 
have demonstrated promising data regarding the acute performance of the Evolut R reporting 
substantially reduced rate of paravalvular regurgitation while 30-day clinical outcomes were similar 
to the CoreValve system (27) (28) (29) (30). However, these findings should be interpreted with 
caution, because of higher risk profiles (higher predicted mortality, lower ejection fraction, higher 
incidence of revascularization procedures) in the CoreValve than Evolut R population (28) (27). 
Moreover, long term clinical outcome data for the Evolut R are limited to the CE mark trial, 
demonstrating excellent clinical results with the highest reported survival at 30 days and 1 year 
(100% and 93.3%, respectively) (18) (19).  
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Thus, we have compared the emerging new generation device, the Evolut R valve with its 
predecessor, the CoreValve, aiming to explore if this step in technology translates to clinical 
outcome differences in the clinical daily routine.  
After propensity analysis, we proved that Evolut R is superior to CoreValve in terms of overall 
survival (p=0.046). In our analysis, 30 days and 1-year survival rates were 99.0% and 85.8%, in 
CoreValve group versus 92.8% and 91.9% in Evolut R group, respectively. For the CoreValve 
group similar survival rate were reported in the self-expanding transcatheter aortic valve U.S. High 
Risk Pivotal Trial: 95.5% at 30 days and 85.1% at 1 year (4). Whereas, for the Evolut R patients, 
survival rates are in line with results of the new generation balloon expandable Sapien 3 valve 
(Edwards Lifesciences) for transfemoral patients: (97.8% at 30 days and 87.7% at 1 year) (31). 
  Vascular adverse events resulting in major or life-threatening bleeding requiring blood transfusion 
are independent predictors of mortality (32). With the first generation device, major vascular 
complications and major bleeding occurred in 16.2% and 16.8% of patients in the PARTNER IB 
(Placement of Aortic Transcatheter Valve) trial (9). Recently the development of low-profile sheath 
has resulted in decreased vascular complications and procedure related bleeding after transfemoral 
TAVI (11). Our study confirms these findings reporting a lower incidence of major vascular 
complications (2.0% vs. 16.1%) and major bleeding (1.4% vs. 9.9%) in patients receiving the new 
self-expanding Evolut R prosthesis compared to patients treated with its predecessor, the 
CoreValve. Notably, comparable results have been described with the new generation balloon 
expandable Sapien 3 valve, showing significantly lower rates of major vascular complications 
(4.5% vs. 16.7%) and major bleeding (2.3% vs. 6.1%) compared to first generation balloon 
expandable Sapien XT (14). Recent reports, including few patients, support our findings reporting a 
numerically (but not significant) less chance to suffer major vascular complication and bleeding 
among patients treated with the Evolut R compared to CoreValve (30) (29). 
  Stroke remains a major risk in the TAVI population. Results from the PARTNER trials showed an 
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almost 2-fold increase in stroke rate in the TAVI arm compared with surgery (3). However, this 
difference disappeared at 2 years follow-up (33). Recent experiences with newer generation devices 
show that the rate of stroke has been decreasing significantly after TAVI (5) (6) (15).  
Unfortunately, we observed a higher incidence of periprocedural major stroke in the Evolut R group 
compared to CoreValve group, although not statistically different (1.4% vs. 0.0%). Recent studies 
have confirmed our result reporting a numerically increased cerebrovascular accident rate for the 
new repositionable valves respect to first generation devices (34) (13) (28) (30) . The resheathing 
and recapture of repositionable valves in ascending aorta can potentially lead to the higher risk of 
embolic events. In our experience another contributing factor to cerebrovascular events for the 
repositionable valve may have been the higher need for postdiltation in the Evolut R cohort. 
Postdilatation is a known predictor of acute cerebrovascular events after TAVI and it has been 
associated with a higher incidence of mortality at 30 days (35). According to our results, a recent 
report suggests that performing predilatation may avoid the need for postdilatation and the possible 
increased risk of embolic events (36).  
  Our matched analysis found a significantly lower pacemaker implantation rate for the Evolut R 
compared to the CoreValve (22.3% vs. 35.0%). A recent meta-analysis included 11.210 patients 
demonstrated that the need for permanent pacemaker implantation ranged from 1% to 51% and was 
in median 28% with the CoreValve device and 6% with the Edwards Sapien device (37). In this 
study, the lower pacing rate for the Evolut R could be attributed to the repositionable and 
recapturable capability enabling more precise valve positioning in order to evade conduction 
disturbances associated to deep implantation. In particular, the ADVANCE II study (the CoreValve 
Prospective International Post-Market Advance II) highlighted the importance of a shallow 
implantation depth to limit the need of permanent pacemaker after TAVI, identifying a cut-off value 
of 4 mm (24). Furtheromore the more conformable nitinol frame design resulting in a reduced 
outward force at the inflow portion of the valve might reduce trauma to the conduction system as 
compared with the CoreValve system (18). According to our findings recent studies have reported a 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 13 
numerically lower chance to require a new permanent pacemaker with the Evolut-R compared with 
the CoreValve, although it was not found to be statistically significant (30) (27).  
 
  Moderate to severe paravalvular leak is frequently observed after TAVI and is associated with 
worse survival (21). In a randomized study comparing the balloon expandable Edwards Sapien XT 
with the self-expandable CoreValve device the risk for moderate or severe paravalvular leak was 
12.4% versus 42.5% immediately after valve placement, which fell to 4.1% and 18.3% after post-
dilatation (38). Potential causes of paravalvular leak include suboptimal positioning, undersizing 
and severe calcification. New devices have been designed to target post TAVI paravalvular leak 
with the introduction of adaptive seal surrounding the ventricular portion of the prosthesis (eg, 
Sapien 3 and Lotus valves) or with the ability to reposition the valve in cases of suboptimal 
deployment (eg, Evolut R and Lotus valves). Recently, authors have reported rates of moderate to 
severe paravalvular leak <2% both for the latest generation of balloon expandable S3 and the 
repositionable Lotus valve (14) (15) (39) (40). Our study confirmed these findings reporting a 
decreased frequency of moderate to severe paravalvular leak at discharge in the Evolut R group 
compared to CoreValve group (9.0% vs. 16.7%; p=0.048). Similar lower rates of clinically relevant 
paravalvular leak for the Evolut R were also observed in recent reports: ranging from 0 to 5% (29) 
(27). A more adaptive frame with an extended skirt and the possibility for a precise positioning may 
explain the downward trend in paravalvular leak rate for the Evolut R respect to the CoreValve.  
   
Limitations. The principal limitations of this study are the relative small sample size and the 
retrospective non-randomized design. Although propensity score matching is a well-accepted 
approach in observational research to address differences in baseline characteristics, it cannot 
account for unmeasured bias. In addition, the echocardiographic assessment of paravalvular leak at 
discharge was not performed by core laboratory evaluation.  
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Conclusion In this retrospective, propensity score-matched analysis, TAVI with the Evolut R was 
associated with a significant survival benefit at 1 year and reduction of vascular access 
complications, bleeding, acute kidney injury and need for permanent pacemaker implantation. The 
clinical significance of these differences needs to be tested in a large randomized, controlled trial. 
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Figures. 
Figure 1: A) Implantation depth evaluated by angiographic images. B) Final aortic regurgitation 
grade evaluated by angiographic images. C) Predischarge paravalvular leak severity evaluated by 
transthoracic echocardiography. 
Figure 2: Kaplan-Meier estimates of 1 year survival. Red line= Evolut R group; blue line= 
CoreValve group. 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 20 
 
Figure 1  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 21 
 
Figure 2  
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Table 1: Baseline characteristics 
 CoreValve group Evolut R group p-value 
 N=211 N=211  
Age, yrs  83 ± 6 82 ± 7 0.252 
Male sex 61 (28.9) 67 (31.8%)  0.525 
Logistic Euroscore, %  20.7 ± 13.4 21.1 ± 12.8 0.546 
STS PROM score, %  7.3 ± 5.4 7.5 ± 6.9 0.609 
Arterial hypertension 189 (89.6%)  184 (87.2%) 0.447 
Diabetes mellitus 23 (10.9%)  25 (11.8%) 0.759 
Coronary artery disease  79 (37.4%) 82 (38.8%) 0.676 
History of myocardial infarction  28 (13.3%)  24 (11.3%) 0.566 
History of percutaneous coronary intervention  52 (24.6%)  44 (20.8%) 0.458 
History of aorto-coronary bypass graft surgery  20 (9.5%) 21 (10.0%) 0.869 
Cerebrovascular disease, n (%) 25 (11.8%) 25 (11.8%) 1.000 
Creatinine (mg/dL) 1.04 (0.9- 1.4) 1.10 (0.9- 1.4) 0.720 
GFR<30 mL/min 41 (19.4%) 46 (21.8%) 0.617 
Atrial fibrillation 16 (7.6%) 23 (10.9%) 0.239 
Peripheral vascular disease  36 (17.1%) 36 (17.1%) 1.000 
Chronic obstructive pulmonary disease 31 (14.7%) 28 (13.3%) 0.674 
Left bundle branch block 13 (6.2%) 11 (5.2%) 0.296 
Right bundle branch block 11 (5.2%) 15 (7.1%) 0.296 
Left anterior hemiblock 21 (10.0%) 15 (7.1%) 0.296 
Prior permanent pacemaker implantation  27 (12.7%)  26 (12.3%) 0.883 
New York Heart Association class ≥ 2 148 (70.1%) 145 (68.7%) 0.751 
Echocardiography data    
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Data shown as n (%) and as means ± (SD); GFR, glomerular filtration rate; STS PROM, STS 
Predicted Risk of Operative Mortality. 
  
   Left ventricle ejection fraction, % 52.9 ± 11.8 54.1 ± 11.6 0.061 
   Left ventricle ejection fraction <35% 189 (90.9%) 182 (92.9%) 0.465 
   Peak aortic gradient, mmHg 79.7 ± 21.3 81.1 ± 20.4 0.501 
   Mean aortic gradient, mmHg 48.6 ± 13.5 48.8 ± 13.2 0.959 
   Aortic valve indexed, cm
2
/m
2
 0.39 ± 0.12 0.36 ± 0.45 0.982 
   Moderate or severe aortic regurgitation  64 (30.1%) 67 (31.7%) 0.514 
   Moderate or severe mitral valve regurgitation 92 (43.6%) 82 (38.8%) 0.778 
   Systolic pressure of pulmonary artery>60 mmHg  15 (7.1%)  13 (6.2%) 0.841 
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Table 2: Procedural data and in hospital outcomes 
 
 
 CoreValve group Evolut R group p-value 
 N=211 N=211  
Device success 204 (96.7%) 209 (99.1%) 0.092 
Procedural access   0.410 
   Femoral  174 (82.5%)  182 (86.2%)  
   Subclavian 27 (12.8%) 19 (9.0%)  
   Aortic  10 (4.7%) 8 (3.7%)  
General anesthesia 51 (24.1%) 48 (22.7%) 0.750 
Procedural time, min 104.0 (60- 142) 100.0 (75- 128) 0.780 
Fluoroscopy time, min 20.3 (16- 28) 22.4 (17- 30) 0.110 
Contrast media, ml 180.0 (120- 230) 150.0 (110- 200) 0.002 
Prosthesis size   0.001 
- 23 mm 10 (4.7%)  27 (12.7%)  
- 26 mm 114 (54.0%) 83 (39.3%)  
- 29 mm  87 (41.2%) 98 (46.4%)  
Predilatation 151 (71.6%) 104 (49.3%) <0.001 
Postdilatation  40 (18.9%) 77 (36.4%) <0.001 
Second valve deployment 2 (0.9%)  1 (0.4%) 0.585 
Conversion to surgery 1 (0.4%)  0 (0.0%) 0.316 
Coronary obstruction   0 (0.0%) 0 (0.0%) --- 
Cardiac tamponade 8 (3.7) 3 (1.4%) 0.123 
Valve malpositioning 2 (0.9%) 0 (0.0%) 0.154 
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In hospital death  6 (2.8%) 1 (0.5%) 0.054 
Any vascular access site complications 47 (22.2%) 20 (9.4%) <0.001 
Major vascular access site complications 34 (16.1%) 5 (2.0%) <0.001 
Life-threatening bleeding 12 (5.7%) 1 (0.4%) <0.001 
Major bleeding  21 (9.9%) 3 (1.4%) <0.001 
Transfusion > 2 blood units  17 (8.1%) 3 (1.4%) 0.001 
Stroke or TIA  3 (1.4%) 5 (2.4%) 0.475 
Major stroke  0 (0.0%) 3 (1.4%) 0.089 
Myocardial infarction 2 (0.9%) 0 (0.0%)  0.156 
Any Acute kidney injury 49 (22.2%) 22 (9.4%) 0.003 
Permanent pacemaker implantation  74 (35.0%) 47 (22.3%) 0.008 
Re-intervention 2 (0.9%)  0 (0.0%)  0.156 
Hospital stay, days 8.8 ± 5.1 7.5 ± 4.6 0.002 
Echocardiography data predischarge (n=174) (n=150)  
   Peak aortic gradient, mmHg 17.8 ± 7.9 16.5 ± 9.1 0.041 
   Mean aortic gradient, mmHg 9.4 ± 4.3 9.2 ± 5.3 0.376 
   Aortic valve area, cm
2
  2.23±3.82 2.86±5.51 0.306 
   Moderate or severe paravalvular leak 26 (16.7%)  12 (9.0%)  0.048 
 
Data shown as n (%) and as means  ± (SD). TIA, transient ischemic attack. 
